Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
[WEBINAR] Molecular bioanalysis considerations along the drug development journey 11 days 20 hours 37 mins 58 secs REGISTER NOW!

Presentation: Metabolomics for discovering the functions of genes with embryonic-lethal mutations (Agilent)

7 Oct 2014
General interest

Presentation held by Steven S. Gross, Department of Pharmacology Weill Cornell Medical College (NY, NY).

sgross

 

Click here to view presentation.

Related Links

  • Agilent Technologies

 

Top content

  • Waters launches the Xevo TQ Absolute XR at ASMS 2025
  • How can diagnostic laboratories accelerate the clinical adoption of allogeneic cell therapies?
  • Why NGS ELN deployments fail

Related tags

metabolomics
Previous article Next article

Related articles

7 OCT 2014 GENERAL INTEREST

Poster: The use of fragment ion and collision cross section for confident identification from LC-ION mobility-MS metabolomics data (Waters Corporation)

31 AUG 2009 DATA PROCESSING AND INTERPRETATION

Biomarkers: unrealized potential in sports doping analysis

8 DEC 2014 CHROMATOGRAPHY

Interview with Arthur Moseley (Duke University) on the Duke Proteomics and Metabolomics Core Facility

3 OCT 2019 JOURNAL ARTICLES

Retention time bracketing for targeted sphingolipidomics by liquid chromatography–tandem mass spectrometry

4 NOV 2014 CHROMATOGRAPHY

Interview with Adam Rosebrock (University of Toronto) on his metabolomics research

20 FEB 2015 CHROMATOGRAPHY

Is there a future for metabotyping in clinical laboratories?

  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
Contact
Contact Us
Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone